EU Approves Novo Nordisk Hemophilia Drug Frehemgo
The European Commission has approved Novo Nordisk to market and sell its hemophilia A drug Frehemgo across Europe.
2026年11月13日
/ DANGDI / DANGDI / DANGDI /The European Commission has approved a new drug from Novo Nordisk. The Danish pharmaceutical giant can now sell its hemophilia treatment Frehemgo in Europe. Novo Nordisk announced the approval in a press release, according to DR.
The decision follows a recommendation from an EMA committee in September. Frehemgo is designed for patients with hemophilia A. Hemophilia A is an inherited condition. Patients with this condition have a reduced ability to clot blood. Because of this, bleeding can be very hard to stop.
About 550 people in Denmark have hemophilia, according to the Danish Hemophilia Society. Novo Nordisk is still awaiting approval to sell Frehemgo in the United States.
Source: DR Nyheder
